Switching From Reference Adalimumab to SB5 (Adalimumab Biosimilar) in Patients With Rheumatoid Arthritis: Fifty‐Two–Week Phase III Randomized Study Results

OBJECTIVE: The 24‐week equivalent efficacy and comparable safety results of the biosimilar SB5 and reference adalimumab (ADA) from the phase III randomized study in patients with moderate‐to‐severe rheumatoid arthritis (RA) have been reported previously. We undertook this transition study to evaluat...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Arthritis Rheumatol
Egile Nagusiak: Weinblatt, Michael E., Baranauskaite, Asta, Dokoupilova, Eva, Zielinska, Agnieszka, Jaworski, Janusz, Racewicz, Artur, Pileckyte, Margarita, Jedrychowicz‐Rosiak, Krystyna, Baek, Inyoung, Ghil, Jeehoon
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: John Wiley and Sons Inc. 2018
Gaiak:
Rheumatoid Arthritis
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC6001519/
https://ncbi.nlm.nih.gov/pubmed/29439289
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/art.40444
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak